Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Releases

164 Press Releases
DateTitleCompany
10 Dec 12 Presentations Highlight Data on VELCADE® (bortezomib) as Retreatment or Maintenance in Patients with Multiple Myeloma Millennium: The Takeda Oncology Company,
Published by
Business Wire
09 Dec 12 Millennium and Takeda Report Data from Phase I Trial of ADCETRIS® (Brentuximab Vedotin) in Front-line Mature T-Cell Lymphomas Millennium: The Takeda Oncology Company,
Published by
Business Wire
09 Dec 12 Once a Week Oral Proteasome Inhibitor MLN9708-Based Therapy Showed High Response Rates in Front-Line Multiple Myeloma Phase 1 / 2 study Millennium: The Takeda Oncology Company,
Published by
Business Wire
06 Nov 12 Takeda to Acquire Envoy Therapeutics, Inc. Envoy Therapeutics Inc. and Takeda Pharmaceutical Company Limited,
Published by
Business Wire
06 Nov 12 VELCADE® (bortezomib), ADCETRIS® (brentuximab vedotin) and Millennium Pipeline Agents to be Featured at American Society of Hematology Annual Meeting Millennium: The Takeda Oncology Company,
Published by
Business Wire
05 Nov 12 CORRECTING and REPLACING Millennium is #1 in Boston Globe Ranking of Top Largest Employer Millennium: The Takeda Oncology Company,
Published by
Business Wire
05 Nov 12 Millennium is #1 in Boston Globe Ranking of Best Large Employers Millennium: The Takeda Oncology Company,
Published by
Business Wire
02 Nov 12 Affymax and Takeda Announce Analyses from OMONTYS® (peginesatide) Injection Phase 3 Dialysis Studies Presented at 2012 American Society of Nephrology Meeting Affymax Inc. and Takeda Pharmaceuticals U.S.A. Inc.,
Published by
Business Wire
01 Nov 12 Millennium and Seattle Genetics Initiate Global Phase 3 Clinical Trial of ADCETRIS® in Previously Untreated Advanced Hodgkin Lymphoma Millennium: The Takeda Oncology Company and Seattle Genetics Inc.,
Published by
Business Wire
31 Oct 12 Takeda and Millennium Announce European Conditional Marketing Authorisation for ADCETRIS® (Brentuximab Vedotin) Millennium: The Takeda Oncology Company,
Published by
Business Wire
31 Oct 12 Millennium and Takeda Announce European Conditional Marketing Authorization for ADCETRIS® (Brentuximab Vedotin) Millennium: The Takeda Oncology Company,
Published by
Business Wire
19 Oct 12 Millennium Initiates Global TOURMALINE-AL1 Pivotal Phase 3 Trial of MLN9708 In Patients with Relapsed or Refractory Primary (AL) Amyloidosis Millennium: The Takeda Oncology Company,
Published by
Business Wire
17 Oct 12 Affymax and Takeda Announce OMONTYS® Data Presentations at the American Society of Nephrology Kidney Week 2012 Affymax Inc. and Takeda Pharmaceuticals U.S.A. Inc.,
Published by
Business Wire
05 Oct 12 Takeda to Acquire LigoCyte Pharmaceuticals, Inc. Takeda
03 Oct 12 TAKEDA AND ADVINUS INITIATE MULTI-YEAR DRUG DISCOVERY COLLABORATION Takeda Pharmaceutical
01 Oct 12 Millennium and Seattle Genetics Highlight Data from ADCETRIS® (Brentuximab Vedotin) Trial in Patients with Newly Diagnosed Systemic Anaplastic Large Cell Lymphoma Millennium: The Takeda Oncology Company,
Published by
Business Wire
26 Sep 12 U.S. Food and Drug Administration Grants Priority Review Status to AMITIZA® (lubiprostone) Submission Seeking Approval for Treatment of Opioid-induced Constipation Sucampo Pharmaceuticals Inc. and Takeda Pharmaceuticals U.S.A. Inc.,
Published by
Business Wire
21 Sep 12 Millennium Ranked In Top 10 Biotech / Biopharmaceutical Companies For 5th Consecutive Year Millennium: The Takeda Oncology Company,
Published by
Business Wire
09 Aug 12 Takeda and Affymax Announce Supply Agreement for OMONTYS® (peginesatide) Injection with U.S. Renal Care, Inc. Takeda Pharmaceuticals U.S.A.,
Published by
Business Wire
27 Jul 12 Sucampo and Takeda Announce Filing of Supplemental New Drug Application for AMITIZA (Lubiprostone) in Opioid-induced Constipation Sucampo Pharmaceuticals Inc. and Takeda,
Published by
Business Wire
20 Jul 12 Millennium and Takeda Announce Positive CHMP Opinion for Conditional Approval of ADCETRIS® (brentuximab vedotin) in Europe Millennium: The Takeda Oncology Company,
Published by
Business Wire
20 Jul 12 Takeda and Millennium Announce Positive CHMP Opinion for Conditional Approval of ADCETRIS® (brentuximab vedotin) in Europe Takeda Pharmaceutical Company Limited,
Published by
Business Wire
12 Jul 12 Takeda and Affymax Announce Supply Agreement for OMONTYS® (peginesatide) Injection with Fresenius Medical Care North America Takeda Pharmaceuticals U.S.A. and Affymax Inc.,
Published by
Business Wire
28 Jun 12 Millennium Initiates TOURMALINE-MM1 Pivotal Phase 3 Trial of MLN9708 in Patients With Relapsed and/or Refractory Multiple Myeloma Millennium: The Takeda Oncology Company,
Published by
Business Wire
14 Jun 12 Millennium Highlights Updated Survival Data from ADCETRIS® (Brentuximab Vedotin) Pivotal Trial in Patients with Relapsed or Refractory Hodgkin Lymphoma Millennium: The Takeda Oncology Company,
Published by
Business Wire
03 Jun 12 ASCO Presentations Highlight Preliminary Results of Studies with MLN9708, First Oral Proteasome Inhibitor in Clinical Trials in Multiple Myeloma Millennium: The Takeda Oncology Company,
Published by
Business Wire
25 May 12 Takeda to Acquire Multilab, Enhancing its Business Infrastructure in Brazil Takeda Pharmaceutical Company Limited
23 May 12 Millennium and Takeda Announce Presentations for Key Investigational Molecules at American Society of Clinical Oncology Annual Meeting Millennium: The Takeda Oncology Company,
Published by
Business Wire
07 May 12 Millennium and Seattle Genetics Initiate Global Phase 3 Trial of ADCETRIS™ in Patients with CD30-Expressing Relapsed Cutaneous T-cell Lymphoma Millennium: The Takeda Oncology Company and Seattle Genetics Inc.,
Published by
Business Wire
11 Apr 12 Takeda to Acquire URL Pharma Takeda Pharmaceutical Company Limited (Takeda),
Published by
F T I Consulting
Advertising